ArticleNucleic acids research2013
Topoisomerase II regulates yeast genes with singular chromatin architectures.
Article in Nucleic acids research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Anticancer drugs targeting topoisomerase II for antifungal treatment.Scientific reports · 2025Article
- Distinct chromosomal "niches" in the genome ofNAR genomics and bioinformatics · 2022Article
- Targeting DNA Topoisomerase II in Antifungal Chemotherapy.Molecules (Basel, Switzerland) · 2022Review
- TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.Journal of ovarian research · 2019Article
- Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells.Scientific reports · 2018Article
- Invisible cities: segregated domains in the yeast genome with distinct structural and functional attributes.Current genetics · 2018Article
- Structure and Chromosomal Organization of Yeast Genes Regulated by Topoisomerase II.International journal of molecular sciences · 2018Review
- Phylogenetic analysis of the core histone doublet and DNA topo II genes of Marseilleviridae: evidence of proto-eukaryotic provenance.Epigenetics & chromatin · 2017Article
- Genome urbanization: clusters of topologically co-regulated genes delineate functional compartments in the genome of Saccharomyces cerevisiae.Nucleic acids research · 2017Article
- Topoisomerase II inhibition suppresses the proliferation of telomerase-negative cancers.Cellular and molecular life sciences : CMLS · 2015Article
- DNA Topoisomerases Are Required for Preinitiation Complex Assembly during GAL Gene Activation.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eukaryotic topoisomerase II (topo II) is the essential decatenase of newly replicated chromosomes and the main relaxase of nucleosomal DNA. Apart from these general tasks, topo II participates in more specialized functions. In mammals, topo IIα interacts with specific RNA polymerases and chromatin-remodeling complexes, whereas topo IIβ regulates developmental genes in conjunction with chromatin remodeling and heterochromatin transitions. Here we show that in budding yeast, topo II regulates the expression of specific gene subsets. To uncover this, we carried out a genomic transcription run-on shortly after the thermal inactivation of topo II. We identified a modest number of genes not involved in the general stress response but strictly dependent on topo II. These genes present distinctive functional and structural traits in comparison with the genome average. Yeast topo II is a positive regulator of genes with well-defined promoter architecture that associates to chromatin remodeling complexes; it is a negative regulator of genes extremely hypo-acetylated with complex promoters and undefined nucleosome positioning, many of which are involved in polyamine transport. These findings indicate that yeast topo II operates on singular chromatin architectures to activate or repress DNA transcription and that this activity produces functional responses to ensure chromatin stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.